FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma

1. FDA approved teclistamab on March 5, 2026. 2. Used with daratumumab for multiple myeloma. 3. Transitioned from accelerated to traditional approval. 4. Efficacy shown in MajesTEC-3 trial. 5. Major risks include cytokine-release syndrome. 6. Available via REMS program. 7. Priority Review designation was granted.